DMBMPP

DMBMPP
Clinical data
Other names	Juncosamine
ATC code	None;
Identifiers
	IUPAC name 2-(2,5-dimethoxy-4-bromobenzyl)-6-(2-methoxyphenyl)piperidine;
CAS Number	1391499-52-7 ;
PubChem CID	72683323;
ChemSpider	59718542;
Chemical and physical data
Formula	C21H26BrNO3
Molar mass	420.347 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(C=C(Br)C(OC)=C1)=C1C[C@@H]2CCC[C@@H](C3=C(OC)C=CC=C3)N2;
	InChI InChI=1S/C21H26BrNO3/c1-24-19-10-5-4-8-16(19)18-9-6-7-15(23-18)11-14-12-21(26-3)17(22)13-20(14)25-2/h4-5,8,10,12-13,15,18,23H,6-7,9,11H2,1-3H3/t15-,18-/m0/s1; Key:KMVGLBONODPTDY-YJBOKZPZSA-N;

DMBMPP, or 2-(2,5-dimethoxy-4-bromobenzyl)-6-(2-methoxyphenyl)piperidine, is a 2-benzylpiperidine analog of the hallucinogenic N-benzylphenethylamine 25B-NBOMe and was discovered in 2011 by Jose Juncosa in the group of David E. Nichols at Purdue University.^[1]^[2] DMBMPP differs from 25B-NBOMe by incorporating the amine within a piperidine ring, making for a more rigid molecular structure than that of the open-chain 25B-NBOMe. The presence of the piperidine ring introduces two stereocenters, thus, four stereoisomers of this compound can be made.

Pharmacology

The (S,S)-isomer ((2S,6S)-DMBMPP) is the most selective agonist for the human 5-HT_2A receptor yet discovered, with a K_i of 2.5 nM at the human 5-HT_2A receptor and with 124-fold selectivity for 5-HT_2A over the structurally similar 5-HT_2C-receptor.^[2] Together with 25CN-NBOH,^[3] (2S,6S)-DMBMPP is the only known 5-HT_2A agonist to exhibit this level of selectivity.

Ligand	K_i ± SEM (nM)	K_i ± SEM (nM)	K_i ± SEM (nM)
	[³H] ketanserin	[³H] mesulergine	fold selectivity
	h5-HT_2A	h5-HT_2C	h5-HT_2C/h5-HT_2A
2C-B	6.0 ± 0.3	23.8 ± 2.6	9.5
25B-NBOMe	0.19 ± 0.01	4.0 ± 0.4	21
(±)-DMBMPP	5.3 ± 0.3	520 ± 22	98
(S,S)-(−)-DMBMPP	2.5 ± 0.1	310 ± 42	124
(R,R)-(+)-DMBMPP	2,100 ± 171	28,600 ± 4700	27

References

^ Juncosa JI (2011-05-07). Organic synthesis combined with molecular modeling: A powerful approach to map the functional topography of dopamine and serotonin receptors (Ph.D. thesis). Purdue University.
^ ^a ^b Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE (January 2013). "Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands". ACS Chemical Neuroscience. 4 (1): 96–109. doi:10.1021/cn3000668. PMC 3547484. PMID 23336049.
^ Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, Kristensen JL (March 2014). "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience. 5 (3): 243–9. doi:10.1021/cn400216u. PMC 3963123. PMID 24397362.

[1] Juncosa JI (2011-05-07). Organic synthesis combined with molecular modeling: A powerful approach to map the functional topography of dopamine and serotonin receptors (Ph.D. thesis). Purdue University.

[Juncosa_2013-2] Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE (January 2013). "Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands". ACS Chemical Neuroscience. 4 (1): 96–109. doi:10.1021/cn3000668. PMC 3547484. PMID 23336049.

[3] Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, Kristensen JL (March 2014). "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience. 5 (3): 243–9. doi:10.1021/cn400216u. PMC 3963123. PMID 24397362.

[1]

[2]

[3]

DMBMPP

Pharmacology

See also

References